News

Printer Friendly Version View printer-friendly version
<< Back
Investigational MEK Inhibitor, ARRY-142886 (AZD6244), Combats Cancer Growth

Potent Oral Efficacy With a Clean Tolerability Profile Demonstrated in Preclinical Models Presented at AACR Conference

ORLANDO, Fla., March 27 /PRNewswire-FirstCall/ -- Kevin Koch, Ph.D., President and Chief Scientific Officer, presented preclinical results for ARRY-142886 (AZD6244), a novel, MEK inhibitor in clinical development discovered by Array BioPharma Inc (Nasdaq: ARRY). The results were described at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Florida in Dr. Koch's presentation titled "ARRY-142886, a novel and highly selective MEK inhibitor in clinical trials." Dr. Koch's presentation was part of the Research Paradigms in Anticancer Drug Discovery and Development Educational Workshop.

Presentation Summary -- ARRY-142886 (AZD6244) Preclinical Results:

Activation of the Ras/Raf/MEK/MAP kinase pathway has been implicated in uncontrolled cell proliferation and tumor growth. ARRY-142886 (AZD6244), a novel, selective, ATP non-competitive inhibitor of MEK 1/2, has nanomolar activity against isolated MEK enzyme and numerous cancer cell lines. ARRY- 142886 (AZD6244) has demonstrated potent oral efficacy in several tumor xenograft models of human cancer, including MIA PaCa2, A549, Colon26, PANC-1, LoVo, Calu6, HCT116, MDA-MB-231, ZR-75-1 and LOX. Array has developed a number of biomarkers to understand on a molecular level the role of MEK in tumor cell proliferation and the relationship between MEK inhibition and certain pathway activating mutations in cancer cells. Strategies in discovery biology, computational sciences, drug design and predictive informatics were described as they relate to increasing clinical success rates of novel therapeutics both generally and specifically to ARRY-142886 (AZD6244).

In addition to Dr. Koch's presentation, scientists from Array will be presenting four scientific posters on ARRY-142886 (AZD6244) on Tuesday, March 30 from 8 am to 12 pm-noon:

     Abstract Number 3888
     "ARRY-142886, a potent and selective MEK inhibitor: I) ATP-independent
     inhibition results in high enzymatic and cellular selectivity"

     Abstract Number 3889
     "ARRY-142886, a potent and selective MEK inhibitor: II) Potency against
     cellular MEK leads to inhibition of cellular proliferation and induction
     of apoptosis in cell lines with mutant Ras or B-Raf"

     Abstract Number 3890
     "ARRY-142886, a potent and selective MEK inhibitor: III) Efficacy in
     murine xenograft models correlates with decreased ERK phosphorylation"

     Abstract Number 3891
     "Preclinical development of ARRY-142886, a potent and selective MEK
     inhibitor"

Please contact Tricia Haugeto at 303-386-1193, or thaugeto@arraybiopharma.com, if you are interested in receiving copies of the posters after they are presented.

About ARRY-142886 (AZD6244)

In December 2003, AstraZeneca AB acquired exclusive, worldwide rights to ARRY-142886 (AZD6244) and related intellectual property for oncology indications. Array recently filed the IND with the Food and Drug Administration and will be responsible for performing a Phase I clinical trial. AstraZeneca is responsible for all other aspects of clinical development and commercialization.

Array plans to commence the Phase I trial shortly at two academic medical centers in the United States. The trial is designed to evaluate tolerability and pharmacokinetics of ARRY-142886 (AZD6244) following oral administration to patients with advanced cancer. In addition, the trial is designed to examine patients for indications of biological activity assessing pharmacodynamic and tumor biomarkers.

About Array BioPharma:

Array BioPharma is creating the next generation of orally active drugs by integrating the latest advances in chemistry, biology and informatics. Our drug development pipeline is focused primarily in cancer and inflammatory disease and includes several promising small molecule drugs that regulate well-validated targets in therapeutically valuable disease pathways. Array collaborates with leading pharmaceutical and biotechnology companies to design, create and optimize drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

Founded in 1998, Array BioPharma is headquartered in Boulder, Colorado and employs over 250, including 200 scientists. Companies utilizing Array's drug discovery expertise include AstraZeneca, Genentech, Eli Lilly, InterMune, GenPath, Roche and Takeda.

About AstraZeneca:

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $18.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.

For more information, please visit www.astrazenecapressoffice.com

Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed in our annual report filed on Form 10-K for the fiscal year ended June 30, 2003, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to collaborate with and fund third parties on their drug discovery activities, the ability of our collaborators and of Array to meet drug discovery objectives tied to milestones and royalties, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, and our ability to attract and retain experienced scientists and management. We are providing this information as of March 27, 2004. We undertake no duty to update any forward- looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

SOURCE Array BioPharma Inc.

-0-

03/27/2004

/CONTACT:
Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, thaugeto@arraybiopharma.com/

/Web site: http://www.astrazenecapressoffice.com /
/Web site: http://www.arraybiopharma.com / (ARRY)

http://www.prnewswire.com